Interneuron Pharmaceuticals Inc. raised $25 million through a private placement of 3.125 million shares of common stock to institutional investors It sold the shares for about $8 per share. As of Dec.
image: Children's research-clinicians created a novel preclinical model that mimics the persistent interneuron loss seen in preterm human infants, identifying interneuron subtypes that could become ...
In order to investigate the effects of perinatal insults on GABAergic interneuron development, the Children's research team, led by Helene Lacaille, Ph.D., in Dr. Penn's laboratory, subjected the new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results